Certara (CERT) is back in focus after announcing a collaboration with NVIDIA to bring the BioNeMo Agent Toolkit into its open integrated AI platform for drug development and biosimulation clients.

Certara's latest AI collaboration comes after a sharp 30 day share price return of 25.27%, although the year to date share price return is down 20.59% and the 1 year total shareholder return has fallen 31.56%. This points to improving short term momentum against a weaker long term record.

If you are interested in where AI driven drug development could go next, it may be worth scanning other healthcare focused AI opportunities through the 39 healthcare AI stocks

Certara has a well defined role in AI driven biosimulation, and the NVIDIA tie up has helped the share price recover some ground. The next step is to see whether that rebound still leaves the stock mispriced.

Most Popular Certara Narrative: 7.2% Undervalued

The most followed narrative currently estimates Certara's fair value at $7.48, slightly above the last close at $6.94, which implies modest upside if those assumptions hold.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base. This is expected to translate to higher recurring revenue and margin expansion through cloud-based SaaS models.

Want to understand why this fair value sits above today's price? The narrative leans on steady revenue expansion, margin repair, and a future earnings profile that assumes investors will pay a premium multiple.

Result: Fair Value of $7.48 (UNDERVALUED)

However, Certara still carries execution risk around AI and acquisition payoffs, and any slowdown in pharma adoption could quickly challenge the current undervalued narrative.

Another View on Certara: Multiples Paint a Tougher Picture

While the SWS DCF model suggests Certara is trading at a discount to its estimated future cash flow value of $13.84, the current P/S ratio of 2.6x looks less forgiving. It sits above both the US Healthcare Services industry at 2.6x and peers at 2.2x, and above a fair ratio of 1.5x. This points to valuation risk if growth or margins fall short.

For investors weighing these conflicting signals, the key question is which yardstick feels more realistic for Certara over the next few years.

Next Steps

After weighing the bullish and cautious angles on Certara, it makes sense to move quickly, review the underlying data yourself, and decide how convincing the upside case really is based on the 2 key rewards

Looking for more investment ideas beyond Certara?

If Certara has piqued your interest, do not stop there. Broaden your watchlist now using focused stock ideas that could sharpen your overall portfolio decisions.

• Target potential mispricings by scanning 45 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying performance.
• Strengthen your income stream by reviewing 9 dividend fortresses that prioritize higher yields supported by solid underlying businesses.
• Lower portfolio stress by assessing 80 resilient stocks with low risk scores that score well on resilience and financial risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.